Since RedHill Biopharma Ltd. (NASDAQ:RDHL) and Arcus Biosciences Inc. (NYSE:RCUS) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation of both companies.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|RedHill Biopharma Ltd.||8.36M||29.13||38.82M||-1.70||0.00|
|Arcus Biosciences Inc.||8.35M||61.53||49.59M||-1.18||0.00|
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 has RedHill Biopharma Ltd. and Arcus Biosciences Inc.’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|RedHill Biopharma Ltd.||-464.35%||0%||0%|
|Arcus Biosciences Inc.||-593.89%||0%||0%|
The Ratings and Recommendations for RedHill Biopharma Ltd. and Arcus Biosciences Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|RedHill Biopharma Ltd.||0||0||2||3.00|
|Arcus Biosciences Inc.||0||0||1||3.00|
RedHill Biopharma Ltd.’s average price target is $16.5, while its potential upside is 90.97%. Competitively the average price target of Arcus Biosciences Inc. is $20, which is potential 73.31% upside. The data from earlier shows that analysts view suggest that RedHill Biopharma Ltd. seems more appealing than Arcus Biosciences Inc.
Insider and Institutional Ownership
RedHill Biopharma Ltd. and Arcus Biosciences Inc. has shares owned by institutional investors as follows: 29.11% and 50.2%. About 19.1% of RedHill Biopharma Ltd.’s share are owned by insiders. Competitively, Arcus Biosciences Inc. has 0.9% of it’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|RedHill Biopharma Ltd.||-1.67%||-7.59%||-6.35%||2.68%||19.47%||38.2%|
|Arcus Biosciences Inc.||2.04%||17.99%||4.17%||-13.85%||0%||11.42%|
For the past year RedHill Biopharma Ltd.’s stock price has bigger growth than Arcus Biosciences Inc.
On 6 of the 9 factors RedHill Biopharma Ltd. beats Arcus Biosciences Inc.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. Its clinical-stage pipeline includes TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in two European Union member states under the European Decentralized Procedure. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.